Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.02 -0.05 (-0.38%)
Streaming Delayed Price Updated: 12:39 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Takeda Pharmaceutical Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Can Japan's Economy Continue To Blossom If Bank of Japan Raises Rates? Apparently So.
Amid an economic climate of high interest rates in the US and a slumber among China stocks led by a downturn in the property market, Japan’s economy lies in stark contrast to the antipathy that... 
Via Benzinga
Topics Economy
Exposures Economy
Morphic Therapeutic's Stock Plunges On Monday - Here's Why?
Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results... 
Via Benzinga
The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days
The company is working on a treatment for ulcerative colitis. But competitive questions linger. 
Via Investor's Business Daily
Looking Into Takeda Pharmaceutical's Recent Short Interest
Via Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
Via Benzinga
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Via The Motley Fool
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now
These two high-yield dividend stocks are attractive buys right now. 
Via The Motley Fool
Top 4 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now?
When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to... 
Via Benzinga
Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan
JP Morgan upgraded ImmunoGen Inc (NASDAQ: IMGN) from Neutral to Overweight with a price target of $22, up from $9, based on insights gathered from a recent physician survey, which focused on the... 
Via Benzinga
ImmunoGen Inks Pact With Takeda To Develop ELAHERE Ovarian Cancer Drug In Japan
ImmunoGen, Inc. (NASDAQ: IMGN) inked pacts with Takeda Pharmaceutical Company Limited (NYSE: TAK) to develop and  
Via Benzinga
How Is The Market Feeling About Takeda Pharmaceutical?
Via Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
Via Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
Via Benzinga
Why Are Poseida Therapeutics Shares Moving Higher Today?
Poseida Therapeutics Inc (NASDAQ: PSTX) shares are trading higher after the company received a $50 million strategic investment by Astellas Pharma Inc (OTC: ALMPY) (OTC: 
Via Benzinga
Disney Considers Different Strategies For Star India, Broadcom Wins Conditional European Approval For VMware Deal, Google Deprioritizes Gen Z Chatbot App: Today's Top Stories
Wall Street Journal 
Via Benzinga
Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement
Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily  
Via Benzinga
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic... 
Via Talk Markets
ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity
The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients... 
Via Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult... 
Via Benzinga
3 AI Stocks That Could Skyrocket Your Wealth
AI is poised to greatly increase the top and bottom lines of many companies, making many AI stocks very attractive at this point. 
Via InvestorPlace
Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting
Seagen Inc (NASDAQ: SGEN) announced updated efficacy and safety results from Part C of phase 2 single-arm trial of Adcetris (brentuximab vedotin) combined with nivolumab and standard chemotherapy... 
Via Benzinga
3 Stocks That Could Skyrocket by This Time Next Summer
The best stocks to skyrocket in June have all done well in 2023 and over the past year. They definitely ought to be on your watchlist. 
Via InvestorPlace
Why Shares of Innate Pharma Jumped Thursday
The company's collaboration agreement with Sanofi could soon pay off. 
Via The Motley Fool
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
The FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active Crohn's disease patients with inadequate response or intolerance to  
Via Benzinga
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'... 
Via Benzinga
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its  
Via Benzinga
Cannabis Movers & Shakers: Latest Appointments From Khiron, MariMed, Equilibria & More
Equilibria Strengthens Women's Wellness With New CSO 
Via Benzinga
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.